Rochester, NY (PRWEB) November 11, 2013
Up to 371 individuals’ jobs are at risk at a pharmaceutical site in the UK (1). The possible, planned layoffs may put R&D personnel and contractors at Novartis West Sussex facility out of work (1). The CBCD believes that these potential layoffs by Novartis may be an example of another pharmaceutical company suffering from an industry wide problem.
That problem is the productivity crisis in pharmaceutical R&D.
The CBCD believes that this crisis is the underlying cause of the planned layoffs. As BBC News reported, “The firm said the (potentially planned layoffs) are a result of a ‘global review’ of its research operations. The jobs of 72 marketing and sales support staff in Frimley, Surrey, are also at risk. The firm said it was proposing to withdraw marketing and sales support for its diabetes and chronic obstructive pulmonary disease products in the UK (1).”
Although Novartis is known for its strong drug pipeline, the CBCD believes that these possible layoffs may be a direct result of the productivity crisis in pharmaceutical R&D, which may finally have hit the pharmaceutical company. As an article published on November 5, 2013 in the industrial daily, FierceBiotech.com reported “The pharma giant hammered the British community two years ago when it eliminated a major manufacturing operation in Horsham. But the Novartis Institutes for BioMedical Research had committed to keeping its research work going and last fall discussed a major upgrade for the site. Today, though, it confirmed that it will shutter the complex, where investigators concentrated on respiratory programs (2).”
Further evidence is the fact that the company is considering a global restructuring of its entire R&D program. “The move signals a wider "realignment" of (Novartis’) R&D worldwide (2).”
The FiercePharma article continued saying, “There's no imme
Copyright©2012 Vocus, Inc.
All rights reserved